uploads///dna _

How Analysts View BioMarin Pharmaceuticals and Peers in April

By

Apr. 25 2018, Updated 10:10 p.m. ET

Company overview

BioMarin Pharmaceuticals (BMRN) is a global biotechnology company focused on the development and commercialization of innovative therapies for serious and life-threatening rare diseases and medical conditions. It targets product candidates that offer a first-to-market opportunity or a significant benefit over existing products.

BioMarin’s product portfolio consists of six commercial-stage products and multiple clinical and pre-clinical product candidates.

Article continues below advertisement

Analysts’ recommendations

Of the 23 analysts covering BioMarin Pharmaceuticals in April, eight analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and four analysts gave it a “hold” rating. The mean rating for the stock is ~1.8 with a target price of $114.30.

Peer ratings

Eleven of the 22 analysts covering Pfizer (PFE) in April gave the stock a “buy” or a higher rating. Nine analysts gave Pfizer a “hold” rating, and two analysts gave it a “strong sell” rating. The mean rating for the stock is ~2.6 with a target price of $40.11.

Of the 12 analysts covering Achaogen (AKAO) in April, five analysts gave the stock a “strong buy” rating, six analysts gave it a “buy” rating, and one analyst gave it a “sell” rating. The mean rating for the stock is ~1.8 with a target price of $21.56.

Of the eight analysts covering CymaBay Therapeutics (CBAY) in April, two analysts gave the stock a “strong buy” rating, and six analysts gave it a “buy” rating. The mean rating for the stock is ~1.8 with a target price of $21.50.

In the next part of this series, we’ll take a look at the therapy portfolio of BioMarin Pharmaceuticals.

Advertisement

More From Market Realist

  • Delta aircraft
    Company & Industry Overviews
    Delta Air Lines Updates Mandatory Vaccine Policy, Explained
  • AMC advertisement in walkway
    Company & Industry Overviews
    Why It's Time for Most Investors to Sell AMC Entertainment Stock
  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • Bitski art and logo
    Company & Industry Overviews
    NFT Platform Provider Bitski Isn’t Publicly Traded
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.